Sesen Bio Overview
- Year Founded
-
2010
- Status
-
Acquired/Merged
- Employees
-
17
- Latest Deal Type
-
M&A
Sesen Bio General Information
Description
Sesen Bio Inc is a late-stage clinical company advancing targeted fusion protein therapeutics for the treatment of patients with cancer. The company's product candidate, Vicineum, also known as VB4-845, is a locally-administered targeted fusion protein composed of an anti-epithelial cell adhesion molecule antibody fragment tethered to a truncated form of Pseudomonas exotoxin A for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG.
Contact Information
Website
www.sesenbio.comCorporate Office
- 245 First Street
- Suite 1800
- Cambridge, MA 02142
- United States
Corporate Office
- 245 First Street
- Suite 1800
- Cambridge, MA 02142
- United States
Sesen Bio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Merger/Acquisition | 07-Mar-2023 | Completed | Generating Revenue | |||
| 6. Secondary Transaction - Open Market | 01-Jun-2021 | Completed | Generating Revenue | |||
| 5. Secondary Transaction - Open Market | 30-Apr-2018 | Completed | Generating Revenue | |||
| 4. PIPE | 25-Nov-2014 | Completed | Generating Revenue | |||
| 3. IPO | 06-Feb-2014 | Completed | Clinical Trials - Phase 3 | |||
| 2. Early Stage VC (Series B) | 08-May-2012 | $20M | $55.2M | Completed | Product Development | |
| 1. Early Stage VC (Series A) | 17-Feb-2010 | $35.2M | $35.2M | Completed | Product Development |
Sesen Bio Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A |
Sesen Bio Comparisons
Industry
Financing
Details
Sesen Bio Competitors (102)
One of Sesen Bio’s 102 competitors is Madrigal Pharmaceuticals, a Corporation company based in West Conshohocken, PA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Madrigal Pharmaceuticals | Corporation | West Conshohocken, PA | ||||
| Peloton Therapeutics | Formerly VC-backed | Dallas, TX | ||||
| Cardiol Therapeutics | Corporation | Oakville, Canada | ||||
| Emmaus Life Sciences | Formerly VC-backed | Torrance, CA | ||||
| Pharmacyclics | Formerly VC-backed | Sunnyvale, CA |
Sesen Bio Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Sesen Bio Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Sesen Bio Former Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Flagship Pioneering | Venture Capital | Minority | ||
| HBM Healthcare Investments | Venture Capital | Minority | ||
| Jafco | Venture Capital | Minority | ||
| Sectoral Asset Management | Venture Capital | Minority | ||
| Third Rock Ventures | Venture Capital | Minority |
Sesen Bio Acquisitions (2)
Sesen Bio’s most recent deal was a Reverse Merger with Carisma Therapeutics for . The deal was made on 07-Mar-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Carisma Therapeutics | 07-Mar-2023 | Reverse Merger | Drug Discovery | ||
| Viventia Bio | 20-Sep-2016 | Merger/Acquisition | Biotechnology |
Sesen Bio ESG
Risk Overview
Risk Rating
Updated October, 26, 2022
32.7 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,638
Rank
Percentile
Pharmaceuticals
Industry
of 1,008
Rank
Percentile
Biotechnology
Subindustry
of 465
Rank
Percentile
Sesen Bio FAQs
-
When was Sesen Bio founded?
Sesen Bio was founded in 2010.
-
Where is Sesen Bio headquartered?
Sesen Bio is headquartered in Cambridge, MA.
-
What is the size of Sesen Bio?
Sesen Bio has 17 total employees.
-
What industry is Sesen Bio in?
Sesen Bio’s primary industry is Drug Discovery.
-
Is Sesen Bio a private or public company?
Sesen Bio is a Private company.
-
What is Sesen Bio’s current revenue?
The current revenue for Sesen Bio is .
-
How much funding has Sesen Bio raised over time?
Sesen Bio has raised $122M.
-
Who are Sesen Bio’s investors?
Flagship Pioneering, HBM Healthcare Investments, Jafco, Sectoral Asset Management, and Third Rock Ventures have invested in Sesen Bio.
-
Who are Sesen Bio’s competitors?
Madrigal Pharmaceuticals, Peloton Therapeutics, Cardiol Therapeutics, Emmaus Life Sciences, and Pharmacyclics are some of the 102 competitors of Sesen Bio.
-
When was Sesen Bio acquired?
Sesen Bio was acquired on 07-Mar-2023.
-
Who acquired Sesen Bio?
Sesen Bio was acquired by Carisma Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
